Evox Therapeutics announced today that it raised $95.4 million (£69.2 million) in a Series C financing round.
Oxford, England-based Evox’s financing was significantly oversubscribed with high demand from both existing and new investors, according to a news release.
Get the full story at our sister site, Drug Delivery Business News.
The FDA announced that it issued emergency use authorization (EUA) for monoclonal antibodies developed by Eli Lilly (NYSE:LLY) for treating COVID-19.
Eli Lilly’s bamlanivimab and etesevimab received authorization to be administered together for treating mild to moderate COVID-19 in adults and pediatric patients over 12 years old and weighing at least 40 kilograms (about 88 pounds), according to a news release. Bamlanivimab had already received an EUA in November 2020 for treating mild-to-moderate COVID-19 cases.
Get the full story at our sister site, Drug Discovery & Development.
The FDA announced that it issued emergency use authorization (EUA) for monoclonal antibodies developed by Eli Lilly (NYSE:LLY) for treating COVID-19.
Eli Lilly’s bamlanivimab and etesevimab received authorization to be administered together for treating mild to moderate COVID-19 in adults and pediatric patients over 12 years old and weighing at least 40 kilograms (about 88 pounds), according to a news release. Bamlanivimab had already received an EUA in November 2020 for treating mild-to-moderate COVID-19 cases.
Authorization for the antibody treatments is for those who test positive for SARS-CoV-2 and are at high risk for progressing to severe COVID-19. The authorized use includes treating those who are 65 years of age or older who have certain chronic medical conditions. Authorization does not include patients who are hospitalized due to COVID-19 or require oxygen therapy due to COVID-19, as the antibodies may be associated with worse clinical outcomes …
Chemical structure of the COVID-19 therapy remdesivir. Image is from Wikipedia.
Last year, FDA approved 53 drugs, leading the industry to describe 2020 as “a strong year for new drug therapy.”
There are several drugs that stand out, according to Todd Wills, the co-author of a study that analyzes how innovative drugs are based on their structure.
The drugs that follow are examples of notable innovative therapies.
[Related: Here’s what molecular shape can tell you about pharma innovation]
1. COVID-19 therapiesOne of the prominent drugs that stands out as structurally novel is remdesivir from Gilead Sciences (NSDQ:GILD). The first COVID-19 treatment to win FDA approval, remdesivir (Veklury), was first developed as an Ebola treatment. But the broad-spectrum antiviral also showed promise against the SARS-CoV-2 virus.
Gilead recently announced that sales of remdesivir beat …
The Galien Foundation recently announced nominees for most innovative pharmaceutical agents for its 14th Annual Prix Galien USA Awards.
The foundation bestows the Prix Galien Award annually to examples of outstanding biomedical, pharmaceutical drugs and medical technology products that are designed to improve the human condition.
“As we celebrate 50 years of the Prix Galien process, we are honored to announce this year’s Prix Galien USA nominees, which represent the determination and passion for change that serves as the driving force of life-changing innovation,” said Sue Desmond-Hellmann, chair of the Prix Galien USA and Prix Galien International Committees, in a news release.
This year, the foundation nominated 26 pharmaceutical agents that have been FDA-approved for the market within the last five years, and show major potential to affect healthcare. The winners will be announced in October this year.
“While scientific discovery and medical in…
The Galien Foundation recently announced nominees for most innovative pharmaceutical agents for its 14th Annual Prix Galien USA Awards.
The foundation bestows the Prix Galien Award annually to examples of outstanding biomedical, pharmaceutical drugs and medical technology products that are designed to improve the human condition.
“As we celebrate 50 years of the Prix Galien process, we are honored to announce this year’s Prix Galien USA nominees, which represent the determination and passion for change that serves as the driving force of life-changing innovation,” said Sue Desmond-Hellmann, chair of the Prix Galien USA and Prix Galien International Committees, in a news release.
This year, the foundation nominated 26 pharmaceutical agents that have been FDA-approved for the market within the last five years, and show major potential to affect healthcare. The winners will be announced in October this year.
“While scientific discovery and medical in…